Pegcetacoplan

Interactions

Pegcetacoplan interacts in the following cases:

End-stage renal disease

There are no data available for the use of pegcetacoplan in patients with end-stage renal disease (ESRD) requiring haemodialysis.

Silica reagents in coagulation panels

There may be interference between silica reagents in coagulation panels and pegcetacoplan that results in artificially prolonged activated partial thromboplastin time (aPTT); therefore, the use of silica reagents in coagulation panels should be avoided.

Pregnancy

There are no or limited amount of data from the use of pegcetacoplan in pregnant women. Studies in animals have shown reproductive toxicity.

Pegcetacoplan is not recommended during pregnancy and in women of childbearing potential not using contraception.

Nursing mothers

It is unknown whether pegcetacoplan is excreted in human milk. The potential for absorption and harm to the breastfed infant is unknown. Animal data suggest a low excretion (less than 1%, not pharmacologically significant) of pegcetacoplan in monkey milk. It is unlikely that a breastfed infant would have clinically relevant exposure.

It is recommended to discontinue breast-feeding during pegcetacoplan treatment.

Carcinogenesis, mutagenesis and fertility

Women of childbearing potential

It is recommended that women of childbearing potential use effective contraception methods to prevent pregnancy during treatment with pegcetacoplan and for at least 8 weeks after the last dose of pegcetacoplan. For women planning to become pregnant, the use of pegcetacoplan may be considered following an assessment of the risks and benefits.

Fertility

No animal or human data on the effect of pegcetacoplan on fertility are available. In toxicity studies, there were no microscopic abnormalities in male or female reproductive organs in monkeys.

Effects on ability to drive and use machines

Pegcetacoplan has no or negligible influence on the ability to drive and use machines.

Adverse reactions


Summary of the safety profile

PNH

The most commonly reported adverse reactions in patients with PNH treated with pegcetacoplan were injection site reactions: injection site erythema, injection site pruritus, injection site swelling, injection site pain, injection site bruising. Other adverse reactions reported in more than 10% of patients during clinical studies were upper respiratory tract infection, diarrhoea, haemolysis, abdominal pain, headache, fatigue, pyrexia, cough, urinary tract infection, vaccination complication, pain in extremity, dizziness, arthralgia and back pain. The most commonly reported serious adverse reactions were haemolysis and sepsis.

C3G and primary IC-MPGN

The most commonly reported adverse drug reactions in patients with C3G or primary IC-MPGN treated with pegcetacoplan were infusion site reactions and upper respiratory tract infections. The most commonly reported serious adverse reactions were acute kidney injury and pneumonia.

Tabulated list of adverse reactions

The table below gives the adverse reactions observed from the clinical studies and postmarketing experience with pegcetacoplan in patients with PNH, C3G and primary IC-MPGN. Adverse reactions are listed by MedDRA system organ class (SOC) and frequency, using the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1 000 to <1/100) or rare (≥1/10 000 to <1/1 000), very rare (<1/10 000), and not known (cannot be estimated from available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

Adverse reactions from clinical trials 1 and postmarketing experience:

MedDRA System Organ Class
Adverse reaction
Frequency in PNHFrequency in C3G or
primary IC-MPGN
Infections and infestations
Influenza Very common
Upper respiratory tract infections2Very commonVery common
Urinary tract infectionVery commonCommon
SepsisCommon3 
Opportunistic infections Common4
COVID-19, Gastrointestinal infection, Fungal
infection, Skin infection, Oral infection
Common 
Ear infectionCommonCommon
Infection, Respiratory tract infection5, Viral
infection, Bacterial infection, Vaginal infection,
Eye infection
Common 
Cervicitis, Groin infectionUncommon 
PneumoniaUncommonCommon
Nasal abscess, Tuberculosis, Oesophageal
candidiasis, COVID-19 pneumonia, Anal abscess
Uncommon 
Immune system disorders
Hypersensitivity reaction Very common6
Blood and lymphatic system disorders
HaemolysisVery common 
ThrombocytopeniaCommonCommon7
NeutropeniaCommonCommon
Metabolism and nutrition disorders
HypokalaemiaCommonCommon
Nervous system disorders
HeadacheVery commonVery common
DizzinessVery common 
Vascular disorders
HypertensionCommon 
Respiratory, thoracic and mediastinal disorders
CoughVery commonCommon
Dyspnoea, Oropharyngeal pain, Nasal congestionCommon 
EpistaxisCommonCommon
Gastrointestinal disorders
Abdominal painVery common 
DiarrhoeaVery commonVery common
NauseaCommonVery common
Skin and subcutaneous tissue disorders
Erythema, Rash, UrticariaCommon 
Musculoskeletal and connective tissue disorders
Arthralgia, Back painVery common 
Pain in extremityVery commonCommon
MyalgiaCommonCommon
Muscle spasmsCommon 
Renal and urinary disorders
Acute kidney injuryCommonVery common
ChromaturiaCommon 
General disorders and administration site conditions
PyrexiaVery commonVery common
FatigueVery commonCommon
Infusion site reactions8Very commonVery common
Investigations
Alanine aminotransferase increased, Bilirubin
increased
Common 
Injury, poisoning and procedural complications
Vaccination complicationVery common 

1 Studies APL2-308, APL2-302, APL2-202, APL2-CP-PNH-204, and APL-CP0514 in PNH patients and Study APL2-C3G-310, APL2-C3G-314, APL2-201 and APL2-C3G-204 in C3G and primary IC-MPGN patients. Medically similar terms are grouped, where appropriate, on the basis of similar medical concept.
2 Include nasopharyngitis, upper respiratory tract infection, pharyngitis, rhinitis and sinusitis.
3 Sepsis includes one case of septic shock and one case with non-encapsulated Neisseria meningitidis.
4 Herpes zoster (including Herpes zoster meningoencephalitis), and Pneumocystis jirovecii infection.
5 Include respiratory tract infection and respiratory tract infection viral.
6 Include rash and eczema.
7 Includes platelet count decreased.
8 PTs included in Infusion site reactions: infusion site erythema, infusion site pruritus, infusion site swelling, infusion site bruising, infusion site pain, infusion site induration.

Description of selected adverse reactions

Infections

No serious infection caused by encapsulated bacteria was reported during PNH Study APL2-302. Forty-eight patients experienced an infection during the study. The most frequent infections in patients treated with pegcetacoplan during PNH Study APL2-302 were upper respiratory tract infection (28 cases, 35%). Most infections reported in patients treated with pegcetacoplan during PNH Study APL2-302 were nonserious, and predominantly mild in intensity. Ten patients developed infections reported as serious including one patient who died due to COVID-19. The most frequent serious infections were sepsis (3 cases) (leading to discontinuation of pegcetacoplan in one patient) and gastroenteritis (3 cases); all of which resolved.

In C3G and primary IC-MPGN clinical studies, four serious respiratory tract infections caused by encapsulated bacteria were reported in patients treated with pegcetacoplan: an epiglottitis, a pneumococcal pneumonia and an atypical pneumonia that led to drug interruption, and a pneumonia Haemophilus with no dose adjustment. Events recovered and resolved except for the events of pneumonia Haemophilus and the atypical pneumonia that resolved with sequelae. In addition, one serious Escherichia urinary tract infection was reported, the event recovered and resolved with no dose adjustment.

Haemolysis

Nineteen patients reported haemolysis during PNH Study APL2-302 in patients treated with pegcetacoplan. Seven cases were reported as serious, and 5 cases led to discontinuation of pegcetacoplan and the dose of pegcetacoplan was increased in 10 patients. There were 3 cases of haemolysis during PNH Study APL2-308 in patients treated with pegcetacoplan. None of these cases were reported as serious or led to discontinuation of pegcetacoplan. The dose of pegcetacoplan was increased in all 3 patients.

Acute kidney injury

In C3G and primary IC-MPGN clinical studies, 10 serious events of acute kidney injury were reported in 8 patients (5.7%) treated with pegcetacoplan, of which 5 events were observed in 4 post-transplant patients. Of these serious events, only 1 led to drug withdrawal and 1 to dose interruption. All events recovered and resolved, except the single event that led to drug withdrawal.

Patients with post-transplant recurrent C3G or primary IC-MPGN

In the patients with post-transplant recurrent C3G or primary IC-MPGN (N=22), included in Studies APL2-C3G-310 and APL2-C3G-204, the safety profile appeared consistent with that of the overall population, although with higher frequencies of severe and serious adverse events, as expected in this patient population.

Paediatric population

In adolescent patients with C3G or primary IC-MPGN (N=28, aged 12 years to 17 years) included in Study APL2-C3G-310, the safety profile appeared consistent with the overall results. The most common adverse reaction reported in this patient population were infusion site reactions. The safety of pegcetacoplan has not been studied in paediatric patients less than 12 years of age.

Cross-check medications

Review your medication to ensure that there are no potentially harmful drug interactions or contraindications.

Ask the Reasoner

Related medicines

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈